The overall mutation frequency of EPHA7 was 2.7% (287/10,437) in TCGA pan-cancer cohort with melanoma (13.6%) ranking first followed by non-small cell lung cancer (5.6%) and endometrial carcinoma (5.6%) (Fig. 4b). This evidence concerns the gene EPHA7 and cancer.